Upload app.py

app.py

@@ -0,0 +1,113 @@
+from summarize import summarize
+from data import data
+import streamlit as st
+
+
+st.write("""
+# AMGEN POC BiTE ReachMD
+""")
+
+st.sidebar.image("./NarrativaLogoBlanco.png")
+
+
+def make_summarizing(new_body, hide=False, num_sentences=3):
+    if hide:
+        return ''
+    result = summarize(
+        new_body, sentence_count=num_sentences, language='english')
+    return result
+
+
+st.subheader("Overview")
+
+
+st.write("""
+         ##### Topics:
+         - Cancer
+         - immuno-oncology
+         - New Therapy
+         - BiTE
+         """)
+st.write("""
+         ##### Summary:
+         """)
+st.write(make_summarizing(data["intro"]))
+st.write('---')
+
+
+st.write('##### Conversation:')
+st.write("""
+         
+         ***Overview of the current therapeutic landscape for cancer and the immuno-oncology***
+         
+         """)
+st.write(make_summarizing(data["block_1"]))
+
+
+st.write("""
+         
+         ***How does the BiTE platform and constituent BiTE molecules actually work***
+         
+         """)
+st.write(make_summarizing(data["block_2"], num_sentences=4))
+
+
+st.write("""
+         
+         ***Where BiTE molecules are currently being studied***
+
+         """)
+st.write(make_summarizing(data["block_3"], num_sentences=3))
+
+
+st.write("""
+         
+         ***Practial approach: Myeloma and BiTE***
+         
+         """)
+st.write(make_summarizing(data["block_4"], num_sentences=6))
+
+
+st.write("""
+         
+         ***Acute Myeloid Leukemia and BiTE molecules***
+
+         """)
+st.write(make_summarizing(data["block_5"], num_sentences=6))
+
+
+st.write("""
+         
+         ***BiTE molecules for solid tumor types***
+
+         """)
+st.write(make_summarizing(data["block_6"], num_sentences=4))
+
+
+st.write("""
+         
+         ***Takeaways***
+
+         """)
+st.write(make_summarizing(data["block_7"], num_sentences=3))
+
+
+st.write("""
+# MRD Slide Deck
+""")
+st.write("""
+         ### Current Landscape in Minimal Residual Disease (MRD) Testing in Hematologic Malignancies
+         """)
+
+
+st.write("""
+        - MRD is the presence of malignant cells under the detection limit of conventional methods
+        - Strong prognostic indicator of patient outcomes
+        - Potential for use in guiding treatment decisions
+            - Intensity of therapy
+            - Appropriateness of SCT
+        - Currently measured using flow cytometry or qPCR
+            - Newer testing methods are emerging
+        - MRD is currently being evaluated as a potential surrogate endpoint, and may have the potential to replace or augment morphological CR as a response criteria in certain hematologic malignancies
+        """)
+